Sleep Disorder Market Report 2026
Sleep Disorder Market Report 2026
Global Outlook – By Disorder Type (Insomnia, Sleep Apnea, Restless Legs Syndrome, Narcolepsy, Circadian Rhythm Disorders), By Treatment (Cognitive Behavioral Therapy, Medication Therapy, Psychiatric Treatment, Behavioral Treatment), By Diagnostic Method (Polysomnography, Home Sleep Testing, Actigraphy, Sleep Diaries, Questionnaires and Screening), By Distribution Channel (Retail Pharmacies, Online Sales, Hospital Pharmacies), By End-User (Hospitals And Sleep Centers, Home Care Settings, Academic ) – Market Size, Trends, Strategies, and Forecast to 2035
Sleep Disorder Market Overview
• Sleep Disorder market size has reached to $33.32 billion in 2025 • Expected to grow to $65.51 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: Rising Stress And Anxiety Levels Fueling The Growth Of The Market Due To Disruption Of Normal Sleep Patterns • Market Trend: Improving Sleep Disorders Treatment With Non-Invasive Electrical Vestibular Nerve Stimulation, Home Use Accessibility, And Clinically Backed Insomnia Relief • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.
What Is Covered Under Sleep Disorder Market?
Sleep disorder refers to a group of conditions that disrupt the body’s natural sleep patterns, affecting the ability to fall asleep, stay asleep, or achieve restorative rest. These disorders can stem from physiological, neurological, or behavioral factors that interfere with healthy sleep cycles. They often lead to impaired daytime functioning, reduced concentration, and negative impacts on overall well-being. The main disorder types of sleep disorder management include insomnia, sleep apnea, restless legs syndrome, narcolepsy, and circadian rhythm disorders. Insomnia refers to a condition characterized by difficulty falling asleep, staying asleep, or experiencing restorative sleep, often requiring targeted interventions to improve sleep quality and overall health. The various treatment options, including cognitive behavioral therapy, medication therapy, psychiatric treatment, and behavioral treatment. The diagnostic methods such as polysomnography, home sleep testing, actigraphy, sleep diaries, and questionnaires or screening. The distributed through retail pharmacies, online sales, and hospital pharmacies and the key end users, including hospitals and sleep centers, home care settings, and academic and research institutes.
What Is The Sleep Disorder Market Size and Share 2026?
The sleep disorder market size has grown rapidly in recent years. It will grow from $33.32 billion in 2025 to $38.23 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increasing awareness about sleep health, rising prevalence of insomnia and sleep apnea, growing adoption of sleep diagnostic services, increasing geriatric population, rising stress and lifestyle-related sleep issues, growing smartphone and wearable device usage for sleep tracking.What Is The Sleep Disorder Market Growth Forecast?
The sleep disorder market size is expected to see rapid growth in the next few years. It will grow to $65.51 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to expansion of telemedicine services for sleep disorders, rising adoption of wearable sleep trackers, increasing home-based diagnostic testing, growth of cognitive behavioral therapy applications, rising government initiatives on sleep health awareness. Major trends in the forecast period include advancement in wearable sleep monitoring devices, advancement in home-based sleep diagnostic tools, advancement in AI-driven sleep analysis, innovation in non-invasive therapies for sleep apnea, innovation in telemedicine for sleep consultation, innovation in cognitive behavioral therapy apps.Global Sleep Disorder Market Segmentation
1) By Disorder Type: Insomnia, Sleep Apnea, Restless Legs Syndrome, Narcolepsy, Circadian Rhythm Disorders 2) By Treatment: Cognitive Behavioral Therapy, Medication Therapy, Psychiatric Treatment, Behavioral Treatment 3) By Diagnostic Method: Polysomnography, Home Sleep Testing, Actigraphy, Sleep Diaries, Questionnaires and Screening 4) By Distribution Channel: Retail Pharmacies, Online Sales, Hospital Pharmacies 5) By End-User: Hospitals And Sleep Centers, Home Care Settings, Academic Subsegments: 1) By Insomnia: Acute Insomnia, Chronic Insomnia, Onset Insomnia, Maintenance Insomnia, Behavioral Insomnia, Medication-Induced Insomnia 2) By Sleep Apnea: Obstructive Sleep Apnea, Central Sleep Apnea, Complex Sleep Apnea Syndrome, Mild Sleep Apnea, Moderate Sleep Apnea, Severe Sleep Apnea, Pediatric Sleep Apnea, Treatment-Resistant Sleep Apnea 3) By Restless Legs Syndrome: Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome, Mild Restless Legs Syndrome, Moderate Restless Legs Syndrome, Severe Restless Legs Syndrome, Intermittent Restless Legs Syndrome, Chronic Persistent Restless Legs Syndrome 4) By Narcolepsy: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia, Pediatric Narcolepsy, Treatment-Resistant Narcolepsy, Secondary Narcolepsy 5) By Circadian Rhythm Disorders: Delayed Sleep Phase Disorder, Advanced Sleep Phase Disorder, Shift Work Sleep Disorder, Jet Lag Disorder, Irregular Sleep-Wake Rhythm Disorder, Non-24-Hour Sleep-Wake DisorderWhat Is The Driver Of The Sleep Disorder Market?
The increasing stress and anxiety levels are expected to propel the growth of the sleep disorder market going forward. Stress and anxiety levels refer to the prevalence of psychological strain and excessive worry within a population, often resulting from environmental, social, or economic pressures. The stress and anxiety levels are increasing due to work-related pressures, as employees face heavier workloads, tight deadlines, and job insecurity. Stress and anxiety levels contribute to sleep disorders by disrupting normal sleep patterns and increasing difficulty in falling or staying asleep. They worsen overall health by impairing restorative sleep, leading to fatigue, cognitive decline, and heightened risk of chronic conditions. For instance, in May?2024, according to the American Psychiatric Association (APA), a US-based professional association, 43% of U.S. adults said they felt more anxious in 2024 than the previous year, up from 37% in 2023 and 32% in 2022. Therefore, increasing stress and anxiety levels are driving the growth of the sleep disorder industry.Key Players In The Global Sleep Disorder Market
Major companies operating in the sleep disorder market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Biogen Inc., Union Chimique Belge S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Neurocrine Biosciences Inc., Harmony Biosciences Holdings Inc., Vanda Pharmaceuticals Inc.Global Sleep Disorder Market Trends and Insights
Major companies operating in the sleep disorder market are focusing on developing advanced therapeutic technologies, such as electrical vestibular nerve stimulation (VeNS) methods, to provide non-drug treatment options that enhance sleep quality, regulate circadian rhythms, and support patients with chronic insomnia. Electrical vestibular nerve stimulation (VeNS) method refers to a non-invasive therapeutic approach that delivers low-level electrical pulses to the vestibular nerve, a key neural pathway to influence brain regions involved in sleep regulation without surgical intervention or pharmaceuticals. For instance, in October 2024, Neurovalens Ltd., a UK–based health-tech company, launched Modius Sleep, an FDA-cleared non-invasive device designed to treat chronic insomnia using electrical vestibular nerve stimulation (VeNS). The headset-style medical device is worn for about 30 minutes each evening, sending safe electrical pulses to the vestibular nerve to influence the hypothalamus and brainstem areas that control circadian rhythm and sleep patterns, helping users fall asleep faster and stay asleep longer.What Are Latest Mergers And Acquisitions In The Sleep Disorder Market?
In July 2023, ResMed Inc., a US‑based provider of sleep and respiratory care solutions, acquired Somnoware Healthcare Systems Inc. for an undisclosed amount. With this acquisition, ResMed expanded its digital health and diagnostic capabilities, integrating Somnoware’s software to enhance the management of sleep disorder diagnosis and patient care across clinics and sleep labs. Somnoware Healthcare Systems Inc. is a US‑based healthcare software company specializing in sleep disorder diagnosis and management solutions.Regional Insights
North America was the largest region in the sleep disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Sleep Disorder Market?
The sleep disorder market consists of revenues earned by entities through sleep clinics, diagnostic sleep studies (polysomnography), cognitive and behavioral sleep therapy, sleep consultation, and monitoring services for sleep-related conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Sleep Disorder Market Report 2026?
The sleep disorder market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sleep disorder industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Sleep Disorder Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $38.23 billion |
| Revenue Forecast In 2035 | $65.51 billion |
| Growth Rate | CAGR of 14.7% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Disorder Type, Treatment, Diagnostic Method, Distribution Channel, End-User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Biogen Inc., Union Chimique Belge S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Neurocrine Biosciences Inc., Harmony Biosciences Holdings Inc., Vanda Pharmaceuticals Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
Frequently Asked Questions
The Sleep Disorder Market Report 2026 market was valued at $33.32 billion in 2025, increased to $38.23 billion in 2026, and is projected to reach $65.51 billion by 2030.
request a sample hereThe expected CAGR for the Sleep Disorder market during the forecast period 2025–2030 is 14.4%.
request a sample hereMajor growth driver of the market includes: Rising Stress And Anxiety Levels Fueling The Growth Of The Market Due To Disruption Of Normal Sleep Patterns in the Sleep Disorder market. For further insights on this market,
request a sample hereThe sleep disorder market covered in this report is segmented –
1) By Disorder Type: Insomnia, Sleep Apnea, Restless Legs Syndrome, Narcolepsy, Circadian Rhythm Disorders
2) By Treatment: Cognitive Behavioral Therapy, Medication Therapy, Psychiatric Treatment, Behavioral Treatment
3) By Diagnostic Method: Polysomnography, Home Sleep Testing, Actigraphy, Sleep Diaries, Questionnaires and Screening
4) By Distribution Channel: Retail Pharmacies, Online Sales, Hospital Pharmacies
5) By End-User: Hospitals And Sleep Centers, Home Care Settings, Academic Subsegments:
1) By Insomnia: Acute Insomnia, Chronic Insomnia, Onset Insomnia, Maintenance Insomnia, Behavioral Insomnia, Medication-Induced Insomnia
2) By Sleep Apnea: Obstructive Sleep Apnea, Central Sleep Apnea, Complex Sleep Apnea Syndrome, Mild Sleep Apnea, Moderate Sleep Apnea, Severe Sleep Apnea, Pediatric Sleep Apnea, Treatment-Resistant Sleep Apnea
3) By Restless Legs Syndrome: Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome, Mild Restless Legs Syndrome, Moderate Restless Legs Syndrome, Severe Restless Legs Syndrome, Intermittent Restless Legs Syndrome, Chronic Persistent Restless Legs Syndrome
4) By Narcolepsy: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia, Pediatric Narcolepsy, Treatment-Resistant Narcolepsy, Secondary Narcolepsy
5) By Circadian Rhythm Disorders: Delayed Sleep Phase Disorder, Advanced Sleep Phase Disorder, Shift Work Sleep Disorder, Jet Lag Disorder, Irregular Sleep-Wake Rhythm Disorder, Non-24-Hour Sleep-Wake Disorder
request a sample here1) By Disorder Type: Insomnia, Sleep Apnea, Restless Legs Syndrome, Narcolepsy, Circadian Rhythm Disorders
2) By Treatment: Cognitive Behavioral Therapy, Medication Therapy, Psychiatric Treatment, Behavioral Treatment
3) By Diagnostic Method: Polysomnography, Home Sleep Testing, Actigraphy, Sleep Diaries, Questionnaires and Screening
4) By Distribution Channel: Retail Pharmacies, Online Sales, Hospital Pharmacies
5) By End-User: Hospitals And Sleep Centers, Home Care Settings, Academic Subsegments:
1) By Insomnia: Acute Insomnia, Chronic Insomnia, Onset Insomnia, Maintenance Insomnia, Behavioral Insomnia, Medication-Induced Insomnia
2) By Sleep Apnea: Obstructive Sleep Apnea, Central Sleep Apnea, Complex Sleep Apnea Syndrome, Mild Sleep Apnea, Moderate Sleep Apnea, Severe Sleep Apnea, Pediatric Sleep Apnea, Treatment-Resistant Sleep Apnea
3) By Restless Legs Syndrome: Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome, Mild Restless Legs Syndrome, Moderate Restless Legs Syndrome, Severe Restless Legs Syndrome, Intermittent Restless Legs Syndrome, Chronic Persistent Restless Legs Syndrome
4) By Narcolepsy: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia, Pediatric Narcolepsy, Treatment-Resistant Narcolepsy, Secondary Narcolepsy
5) By Circadian Rhythm Disorders: Delayed Sleep Phase Disorder, Advanced Sleep Phase Disorder, Shift Work Sleep Disorder, Jet Lag Disorder, Irregular Sleep-Wake Rhythm Disorder, Non-24-Hour Sleep-Wake Disorder
Major trend in this market includes: Improving Sleep Disorders Treatment With Non-Invasive Electrical Vestibular Nerve Stimulation, Home Use Accessibility, And Clinically Backed Insomnia Relief For further insights on this market,
request a sample hereMajor companies operating in the Sleep Disorder market are Major companies operating in the sleep disorder market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Biogen Inc., Union Chimique Belge S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Neurocrine Biosciences Inc., Harmony Biosciences Holdings Inc., Vanda Pharmaceuticals Inc.
request a sample hereNorth America was the largest region in the sleep disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sleep disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
request a sample here